Intelectin-2: Gut Protein Boosts Immunity & Fights Antibiotic Resistance

A newly discovered protein in the gut, intelectin-2, shows promise in both bolstering the intestinal barrier and directly neutralizing harmful bacteria, according to research from MIT. The findings, published in Nature Communications, suggest a potential new avenue for treating gastrointestinal diseases and combating antibiotic-resistant infections. This protein appears to operate on two fronts: strengthening the protective mucus layer lining the digestive tract and, if that layer is breached, directly trapping and eliminating invading bacteria.

How Intelectin-2 Works: A Two-Pronged Defense

The body’s mucosal surfaces, including those lining the gut, are naturally equipped with defensive molecules. Among these are lectins – proteins that recognize and bind to sugars found on the surfaces of cells, including both host tissues and microbes. Researchers have identified intelectin-2 as a particularly effective antimicrobial lectin within the gastrointestinal tract. The protein functions by attaching to sugar molecules on bacterial membranes, effectively trapping the bacteria and hindering their growth. Crucially, it also strengthens the existing mucus barrier, providing an initial line of defense.

“What’s remarkable is that intelectin-2 operates in two complementary ways. It helps stabilize the mucus layer, and if that barrier is compromised, it can directly neutralize or restrain bacteria that begin to escape,” explains Laura Kiessling, the Novartis Professor of Chemistry at MIT and the study’s senior author. MIT News

The mechanism involves binding to a sugar molecule called galactose, commonly found in mucins – the primary component of mucus. By linking mucin molecules together, intelectin-2 reinforces the structural integrity of the mucus layer. However, galactose is also present on the surface of some bacterial cells. This allows intelectin-2 to directly bind to and disrupt the membranes of pathogens, ultimately leading to their demise. This antimicrobial effect has been observed against a range of bacteria, including some strains resistant to traditional antibiotics.

Beyond the Gut: Broader Implications for Mucosal Immunity

While the initial research focused on the gastrointestinal tract, the implications extend to other mucosal surfaces within the body, such as those found in the respiratory system. Nature reports that intelectin-2’s ability to recognize microbes within microbial communities is not limited to the gut, encompassing both gram-positive and gram-negative bacteria from both the respiratory and gastrointestinal tracts. This suggests a broader role in mucosal defense throughout the body.

The study highlights the complex interplay between lectins, mucins, and the microbiome. Mammals regulate the composition and activity of their native microbiota at colonization sites, and lectins like intelectin-2 play a crucial role in influencing these microbial populations. Understanding these interactions is key to developing strategies for maintaining a healthy microbiome and preventing infections.

Human vs. Mouse Intelectin-2: A Subtle Difference

Interestingly, the production of intelectin-2 differs between humans and mice. In humans, the protein is consistently produced by Paneth cells in the small intestine. Paneth cells are specialized epithelial cells responsible for secreting antimicrobial substances. However, in mice, intelectin-2 production appears to be triggered by inflammation or parasitic infections, primarily originating from mucus-secreting Goblet cells. This difference may influence how the protein functions in different species and could be a factor to consider when translating research findings to human applications.

The Role of Intelectin-2 in Inflammatory Bowel Disease

The research also sheds light on the potential role of intelectin-2 in inflammatory bowel disease (IBD). Levels of the protein can be abnormally low or high in individuals with IBD. Reduced levels may weaken the mucus barrier, increasing susceptibility to infection, while excessive amounts could disrupt the balance of the gut microbiome by eliminating beneficial bacteria. PubMed details these findings, suggesting that therapies aimed at restoring balanced levels of intelectin-2 could offer a novel approach to managing IBD.

Evidence and Limitations of the Study

The MIT study involved both in vitro experiments (conducted in a lab setting) and in vivo studies (conducted in living organisms, specifically mice). Researchers demonstrated that intelectin-2 could bind to both mucins and bacterial carbohydrates, and that this binding led to microbial death. However, it’s important to note that the in vivo studies were conducted in mice, and further research is needed to confirm these findings in humans. The study also doesn’t fully elucidate the precise signaling pathways involved in intelectin-2 production and regulation.

The research team, led by Amanda Dugan and Deepsing Syangtan, acknowledges that further investigation is needed to fully understand the complex interactions between intelectin-2, the microbiome, and the host immune system. The sample size used in the study, while sufficient for initial findings, may require expansion to confirm the robustness of the results.

Future Directions: Harnessing Intelectin-2 for Therapeutic Applications

The researchers are optimistic about the potential of intelectin-2 as a therapeutic tool. Kiessling envisions exploiting the protein’s properties to design new therapies that reinforce the mucus barrier and combat antibiotic-resistant bacteria. “Harnessing human lectins as tools to combat antimicrobial resistance opens up a fundamentally new strategy that draws on our own innate immune defenses,” she states.

The next steps involve further characterizing the protein’s structure and function, conducting clinical trials to assess its safety and efficacy in humans, and exploring the possibility of developing intelectin-2-based therapies for a range of gastrointestinal and respiratory diseases. The team is also investigating the potential for modulating intelectin-2 levels through dietary interventions or other lifestyle modifications. Ongoing research will focus on understanding the long-term effects of intelectin-2 manipulation and identifying potential off-target effects.